Episode 39. ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel Blood Cancer Talks

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed:
1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
 
https://ash.confex.com/ash/2023/webprogram/Paper173509.html
 
2. MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
 
https://ash.confex.com/ash/2023/webprogram/Paper179141.html
 
3. Venetoclax + Decitabine vs 7+3 in AML
 
https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax
 
4. FILO study: Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. 
https://ash.confex.com/ash/2023/webprogram/Paper185437.html 
 
5. AUGMENT-101: Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results
 
https://ash.confex.com/ash/2023/webprogram/Paper172422.html
 
6. VEN+HMA in HR MDS: Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
 
https://ash.confex.com/ash/2020/webprogram/Paper139492.html